No articles found for this sector...

================================================================================

No articles found for this sector...

================================================================================

[TITLE]Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference:
[TEXT]
ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 4:00 p.m. ET at the Lotte New York Palace in New York City.

Investors interested in arranging a meeting with company management during the conference should contact the Piper Sandler conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section of the Supernus Pharmaceuticals website at www.supernus.com . An archived replay of the webcasts will be available for 60 days on the Company's website following the conference.
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3193017/19871/en/Supernus-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html


[TITLE]BK Virus Infection Market Trends, Strategies and Business Prospects 2025-2035 - Lack of FDA-Approved Drugs Spurs Innovation in BK Virus Treatment:
[TEXT]
Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "BK Virus Infection Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.

The key drivers propelling the BK virus infection drug market stem largely from the growing immunocompromised patient population. Organ transplantation, particularly kidney transplants, is increasing globally. For instance, the United Network for Organ Sharing (UNOS) reported over 23,000 kidney transplants in the US alone in 2023, a population highly vulnerable to BKV reactivation. This surge directly increases the demand for effective management of BKV infections.

Furthermore, awareness of BKV-related complications among nephrologists and transplant surgeons has risen, leading to routine BKV screening post-transplant, which further stimulates the market for therapeutic drugs. Off-label use of antivirals such as cidofovir and leflunomide remains prevalent despite their nephrotoxicity and limited efficacy, underscoring the urgent need for targeted drug development. Additionally, widespread immunosuppressive regimens, essential to prevent graft rejection, inadvertently increase susceptibility to BKV reactivation, making antiviral treatment options a critical unmet need.

Despite growing awareness and demand, several challenges constrain the BK virus infection drug market. Foremost is the absence of FDA-approved antiviral agents specifically targeting BKV, which forces clinicians to rely on off-label medications. Both drugs, while somewhat effective, are associated with significant side effects; for example, nephrotoxicity can exacerbate kidney damage, a grave concern for transplant patients.

Managing the delicate balance between reducing immunosuppression to control the virus and maintaining sufficient immunosuppression to prevent graft rejection adds complexity to treatment protocols, making standardized drug regimens elusive. Financial barriers also exist high costs associated with frequent viral load monitoring and long-term therapy can restrict access, especially in resource-limited settings such as parts of Southeast Asia and Africa, where transplant infrastructure is growing but limited.

However, the BK virus infection market holds several promising opportunities for innovation and growth. Drug developers are increasingly focusing on creating targeted antiviral agents that inhibit specific stages of BKV replication, potentially improving efficacy while minimizing side effects. For example, AlloVir is advancing adoptive T-cell therapies that harness the patient's immune cells to specifically attack BKV-infected cells a personalized treatment approach showing encouraging early clinical results. This form of immunotherapy could revolutionize BKV management, reducing dependence on toxic antivirals.

Additionally, integrating companion diagnostics with therapeutic regimens presents an opportunity for precision medicine; real-time viral load tracking via sensitive PCR assays allows clinicians to tailor therapy intensity, improving patient outcomes. Combination therapies that pair antivirals with immune modulators are also under exploration, aiming to simultaneously suppress viral replication and optimize immune response. Market expansion in emerging economies is noteworthy. This expanding transplant ecosystem, combined with increasing healthcare investments, creates fertile ground for introducing novel BKV therapies.

Moreover, market trends reflect broader shifts in medical innovation and healthcare delivery. Precision medicine is becoming central to BKV management, with clinicians tailoring treatment based on viral load measurements and patient-specific immune profiles. For example, many transplant centers in the U.S. and Europe have adopted routine BKV viral load monitoring protocols to guide immunosuppressant adjustments and antiviral use, minimizing overtreatment.

Investment in immunotherapies like adoptive T-cell therapy is growing, reflecting confidence in cell-based approaches to control persistent viral infections. The use of biomarkers and molecular diagnostics is influencing not only clinical practice but also drug development pipelines, with pharmaceutical companies increasingly developing integrated solutions that combine diagnostics with therapeutics. Collaborations between biotech firms and leading transplant centers, such as the partnership between AlloVir and academic institutions, accelerate clinical trials and validation.

The current therapeutic landscape is dominated by off-label use of antivirals like cidofovir and leflunomide. Despite their limitations, these drugs remain the mainstay of BKV treatment due to the absence of approved alternatives. For example, a multicenter study in Europe highlighted the cautious use of leflunomide to reduce viral load but also noted significant side effects limiting broader adoption.

Emerging players such as AlloVir are shifting the paradigm by developing adoptive T-cell therapies that target BKV with high specificity, positioning themselves as leaders in immunotherapeutic innovation. Large pharmaceutical companies are also exploring antiviral candidates with activity against polyomaviruses, seeking to fill the gap in approved treatments.

Market Dynamics:

Drivers Increasing incidences of BK virus infections among organ transplant recipients. Rising awareness and advancements in diagnostic technologies. Growing demand for effective antiviral drugs.

Challenges Lack of effective treatment options currently available in the market. High costs associated with the development of new therapeutics.

Case Studies Implementation of new diagnostic standards in the U.S. hospitals.

Industry Trends Focus on personalized medicine and targeted therapies for BK virus infections.

Opportunities Expansion of research and development for novel therapeutic solutions. Potential market growth in emerging economies due to rising healthcare infrastructure.

Company Profiles:

Kalaris Therapeutics (AlloVir)

Hybridize Therapeutics

Orthogon Therapeutics

Vera Therapeutics, Inc.

AiCuris

Memo Therapeutics AG

SymBio Pharmaceuticals Limited
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192888/28124/en/BK-Virus-Infection-Market-Trends-Strategies-and-Business-Prospects-2025-2035-Lack-of-FDA-Approved-Drugs-Spurs-Innovation-in-BK-Virus-Treatment.html


[TITLE]Digital Transformation in Healthcare Market Size to Reach USD 258.22 Billion by 2033 Driven by Technology Adoption and Patient Centric Care – SNS Insider:
[TEXT]
Austin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- According to S&S Insider, the global Digital Transformation in Healthcare
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192874/0/en/Digital-Transformation-in-Healthcare-Market-Size-to-Reach-USD-258-22-Billion-by-2033-Driven-by-Technology-Adoption-and-Patient-Centric-Care-SNS-Insider.html


[TITLE]Asthma and COPD Drugs Market to Reach USD 50.42 Billion by 2033, Driven by Rising Prevalence of Respiratory Disorders and Growing Adoption of Combination Therapies – SNS Insider:
[TEXT]
Austin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Asthma and COPD Drugs
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192846/0/en/Asthma-and-COPD-Drugs-Market-to-Reach-USD-50-42-Billion-by-2033-Driven-by-Rising-Prevalence-of-Respiratory-Disorders-and-Growing-Adoption-of-Combination-Therapies-SNS-Insider.html


===== Company info for companies mentioned in news =====

Company name: anaptysbio
symbol: ANAB
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1764032916
name: anaptysbio
------------------------------------------------------------------

Company name: bk virus
name: bk virus
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: sns insider
name: sns insider
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: supernus pharmaceuticals
name: supernus pharmaceuticals
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=supernus+pharmaceuticals&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

================================================================================

[TITLE]Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View:
[TEXT]
Celcuity Inc. (NASDAQ:CELC) is among the hottest SMID-cap stocks so far in 2025. Following recent clinical progress, Wolfe Research initiated coverage on Celcuity on November 17, with an Outperform rating and a $110 price target, according to TheFly.

Likoper/Shutterstock.com

The firm highlighted the company’s strong momentum following the recent Phase 3 success for gedatolisib in second-line PIK3CA-WT breast cancer. With that success, it believes that the upcoming PIK3CA-mt readout should be a key catalyst in 2026. In addition, Wolfe Research believes that continued clinical progress has strengthened the company’s strategic value, positioning Celcuity as a compelling acquisition target for large pharmaceutical companies.

On the same day, November 17, the company announced that it had submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib.

Earlier, on October 18, the company had announced detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib at the European Society for Medical Oncology (ESMO) Congress. The data indicated a significant improvement through the therapy, with up to a 76% reduction in the risk of disease progression or death.

Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company pursuing the development of targeted therapies for oncology.

While we acknowledge the potential of CELC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Most Fantastic Stocks Every Investor Should Pay Attention To and 13 Best Stocks to Buy According to Citadel LLC.

Disclosure: None. This article is originally published at Insider Monkey.
[Source link]: https://finance.yahoo.com/news/celcuity-celc-clinical-success-m-120200224.html


[Failed to load article at https://www.globenewire.com/news-release/2025/11/21/3192889/0/en/Oncology-Biomarker-Market-Accelerates-Toward-USD-113-5-Billion-by-2034.html]


[TITLE]Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | According to DataM Intelligence:
[TEXT]
AUSTIN, Texas and TOKYO, Nov. 21, 2025 /PRNewswire/ -- According to DataM Intelligence, the Prostate Cancer Drugs
[Source link]: https://www.prnewswire.co.uk/news-releases/prostate-cancer-drugs-market-to-reach-usd-28-10-billion-by-2033--according-to-datam-intelligence-302623116.html


[TITLE]Biotechnology CMO and CDMO Market on Track for USD 199.67 Billion by 2034 with a Strong 11.54% CAGR:
[TEXT]
Ottawa, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The global biotechnology CMO and CDMO
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192861/0/en/Biotechnology-CMO-and-CDMO-Market-on-Track-for-USD-199-67-Billion-by-2034-with-a-Strong-11-54-CAGR.html


===== Company info for companies mentioned in news =====

Company name: bioatla
symbol: BCAB
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1764032919
name: bioatla
------------------------------------------------------------------

Company name: celcuity
symbol: CELC
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1764032921
name: celcuity
------------------------------------------------------------------

Company name: datam intelligence
name: datam intelligence
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: oncology
symbol: 3NK.F
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1764032922
name: oncology
------------------------------------------------------------------

================================================================================

No articles found for this sector...

================================================================================

